Fundz

Who to call at NetraMark, and when

Fundz watches for the moments NetraMark starts buying, and tells you who to reach.

  • An alert the day NetraMark raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at NetraMark, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at NetraMark. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

NetraMark secures a contract backlog of C$2.5 million, aiming for C$8-10 million by mid-2026.

Dec 18, 2025

Contract Type

contract

TorontoBiotechnologyHealth CareArtificial IntelligenceMedical

Description

NetraMark Holdings Inc. announced a significant increase in its contract backlog to approximately C$2.5 million, driven by new project commitments. This milestone reflects growing demand for its NetraAI platform and aligns with the company’s objectives for future growth in clinical trial optimization.

Quick answer

NetraMark secures a contract backlog of C$2.5 million, aiming for C$8-10 million by mid-2026. (December 18, 2025). NetraMark is based in Toronto, Ontario, Canada.

What agreement did NetraMark announce on December 18, 2025?
NetraMark Holdings Inc. announced a significant increase in its contract backlog to approximately C$2.5 million, driven by new project commitments. This milestone reflects growing demand for its NetraAI platform and aligns with the company’s objectives for future growth in clinical trial optimization.
What does NetraMark do?
NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry.
Where is NetraMark based?
NetraMark is based in Toronto, Ontario, Canada.

Source: Fundz verified event record.

Company Information

Company

NetraMark

Location

Toronto, Ontario, Canada

About

NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

Related People

Luca
Senior decision-maker at this company
••••••••@••••••••

See Luca's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for NetraMark's next move

Learn about Strategic plan

NetraMark signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.